Onco-Innovations Secures C$5 Million to Advance Cancer Drug ONC010

Onco-Innovations Limited, a Canadian oncology company, has announced a non-brokered private placement expected to raise approximately C$5 million, with proceeds earmarked to advance its lead drug candidate ONC010 through manufacturing and preclinical testing. The financing, comprising 6,764,069 units priced at C$0.7392 per unit, is set to close on or about July 10, 2026, subject to regulatory approvals including from Cboe Canada.

Each unit consists of one common share and one warrant exercisable at C$0.90 per share for a period of three years. The offering is conducted under Canada’s Listed Issuer Financing Exemption, meaning the securities issued will not be subject to a hold period under applicable Canadian securities laws. The company stated that funds will also support development of its SynoGraph platform and provide working capital for general corporate purposes.

The announcement underscores Onco-Innovations’ commitment to its ONC010 program, which targets solid tumors through patented technology for which the company holds an exclusive worldwide license. Solid tumors represent a significant challenge in oncology, accounting for the majority of cancer cases, and innovative therapies are urgently needed. This capital injection enables the company to move ONC010 closer to clinical trials, a critical step in validating its therapeutic potential.

For investors, the private placement offers an opportunity to participate in the company’s growth while providing Onco-Innovations with the financial runway to execute its development plan. The inclusion of warrants with a three-year exercise period above the offering price suggests confidence in future value creation. The news is particularly relevant given the high unmet need in solid tumor treatment and the company’s focus on novel mechanisms of action.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

More details on the press release can be found at https://www.nnw.fm/QatCe. For the latest news and updates on ONNVF, visit the company’s newsroom at https://nnw.fm/ONNVF.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Onco-Innovations Secures C$5 Million to Advance Cancer Drug ONC010.

The post Onco-Innovations Secures C$5 Million to Advance Cancer Drug ONC010 appeared first on citybuzz.